Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.73 |
| ▸ | CNR1 | P21554 | 2/20 | 0.73 |
| ▸ | CNR2 | P34972 | 2/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.66 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.66 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | CASP2 | P42575 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 4/20 | 0.59 |
| ▸ | PPARD | Q03181 | 4/20 | 0.59 |
| ▸ | PPARA | Q07869 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.59 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.59 |
| ▸ | TLR2 | O60603 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828949 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL4000461 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL531436 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL9193102 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL5964111 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL3990517 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL9256918 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL31529340 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL7147169 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A | |
| SCHEMBL532448 | 0.98 | FAAH (0.76) | FAAHCNR1CNR2EPHX2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005622-A | Composition for improving, preventing or treating vaginitis or vulvitis comprising lactobacillus salivarius HHuMin-U | 比菲德股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | MEDIHELPLINE CO., LTD (KR) | 2026-05-05 | — | — | US | disclosed |
| US-20250082592-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2025-03-13 | — | — | US | disclosed |
| US-20250032385-A1 | FUNCTIONAL COMPOSITION FOR ALOPECIA COMPRISING CENTIPEDA MINIMA-DERIVED EXTRACT | D-NATURE CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250025523-A1 | COMPOSITION FOR PREVENTING OR TREATING MUSCLE DISEASE COMPRISING SARGASSUM SERRATIFOLIUM EXTRACT | Pukyong National University Industry- University Cooperation Foundation (KR) | 2025-01-23 | — | — | US | disclosed |
| EP-4186516-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GRAPHENE QUANTUM DOTS FOR USE IN THE TREATMENT OF VIRAL DISEASES CAUSED BY ADENOVIRUS INFECTIONS | BIOGRAPHENE INC (KR) | 2024-12-11 | — | — | EP | disclosed |
| US-20240358779-A1 | EXTRACELLULAR VESICLES DERIVED FROM LACTOBACILLUS BACTERIA, AND USE THEREOF | MD HEALTHCARE INC. (KR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024196194-A1 | NOVEL ENTEROCOCCUS FAECALIS HL1 STRAIN AND USE THEREOF | 재단법인 아산사회복지재단 | 2024-09-26 | — | — | WO | disclosed |
| WO-2024181594-A1 | BROCCOLI SPROUT FERMENTATION METHOD TO INCREASE ACTIVE INGREDIENT CONTENT, AND BROCCOLI SPROUT POWDER PRODUCED THEREBY | 주식회사 컴투네이처 | 2024-09-06 | — | — | WO | disclosed |
| US-20240269201-A1 | LACTOBACILLUS ACIDOPHILUS-DERIVED VESICLES AND USE THEREOF | MD HEALTHCARE INC. (KR) | 2024-08-15 | — | — | US | disclosed |
| US-20020009472-A1 | Cosmetics | KYOWA HAKKO BIO CO., LTD. (JP) | 2002-01-24 | — | — | US | disclosed |
| EP-1166767-A2 | Skin care product containing hydroxyproline or N-acylated hydroxyproline derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1159952-A1 | COSMETICS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-12-05 | — | — | EP | disclosed |
| EP-0445785-B1 | Plate-like barium sulfate and cosmetic composition | KAO CORP (JP) | 1995-08-09 | — | — | EP | disclosed |
| US-5340582-A | Crystal structure, optical characteristics | KAO CORPORATION (JP) | 1994-08-23 | — | — | US | disclosed |
| US-5262148-A | HEATING A BARIUM SALT AND A SULFATE UNDER ACIDIC CONDITIONS TO REACT, FORMING BARIUM SULFATE HAVING A PLATE CRYSTAL STRUCTURE | KAO CORPORATION (JP) | 1993-11-16 | — | — | US | disclosed |
| US-5171572-A | BARIUM SULFATE AND COSMETIC COMPOSITIONS COMPRISING SAME | KAO CORPORATION (JP) | 1992-12-15 | — | — | US | disclosed |
| US-5167709-A | Improved spreadability | KAO CORPORATION (JP) | 1992-12-01 | — | — | US | disclosed |
| EP-0455018-A1 | Pigment consisting of polyvalent metal salt of amidosulfonic acid and cosmetic composition containing the same | KAO CORPORATION (JP) | 1991-11-06 | — | — | EP | disclosed |
| EP-0445785-A1 | Plate-like barium sulfate and cosmetic composition | KAO CORPORATION (JP) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082592-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION OR TREATMENT OF SARCOPENIA, CONTAINING ROR-alpha ACTIVATOR JC1-40 | TFAM, RORA, CKMT1A; CKMT1B | FAAH 4759/4885CNR1 2700/4885CNR2 3844/4885 |
| US-20250032385-A1 | FUNCTIONAL COMPOSITION FOR ALOPECIA COMPRISING CENTIPEDA MINIMA-DERIVED EXTRACT | BTN3A1, NGF, BBC3 | FAAH 190/4885CNR1 1031/4885CNR2 812/4885 |
| US-12616730-B2 | Topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | CUTA, VEGFA, MMP8 | FAAH 1807/4885CNR1 2235/4885CNR2 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.